STOCK TITAN

SS Innovations Provides Update on Continuing Progress and Milestones

SS Innovations highlights rapid growth in SSi Mantra installations, procedures and telesurgery while outlining anticipated U.S. and EU regulatory timelines.

(Moderate)
(Very Positive)
Tags

SS Innovations (SSII) reported continued global expansion and growing utilization of its SSi Mantra surgical robotic system as of early September 2026.

The installed base reached 238 systems on September 8, 2026, up 42% from 168 at the end of 2025. Cumulative multi-specialty procedures increased to 14,103, a 79% rise from 7,885 at the end of 2025, with approximately 1,500 physicians trained and more than 170 procedure types performed. The global footprint now spans 12 countries, including new installations in Colombia and Sri Lanka and expanding telesurgery use in India and the Philippines.

Milestones include the first totally endoscopic beating-heart bypass in Colombia, a robotic pyeloplasty on a 45-day-old infant in India, a telesurgery over 13,600 miles between Colombia and India, and 50 robotic surgeries in a single day using five systems. The company expects FDA 510(k) review completion by the end of Q1 2027 and EU CE marking by the end of 2026.

Loading...
Loading translation...

Positive

  • Installed base 238 systems on Sept. 8, 2026, up 42% from 168 at 2025 year-end
  • 14,103 cumulative procedures as of Sept. 8, 2026, up 79% from 7,885 at 2025 year-end
  • Global presence in 12 countries including new installations in Sri Lanka and Colombia
  • 258 pediatric robotic surgeries completed with SSi Mantra as of Aug. 31, 2026
  • 188 telesurgeries completed with SSi Mantra as of Aug. 31, 2026
  • Approx. 1,500 physicians trained and over 170 procedure types performed using SSi Mantra

Negative

  • None.

Market Context

The prior August 13 earnings report recorded 224 installed systems and 12,272 cumulative surgeries, ...
Analysis

The prior August 13 earnings report recorded 224 installed systems and 12,272 cumulative surgeries, providing a directly comparable baseline for this update’s expanded operating metrics.

Key Figures

Global installed base: 238 systems Installed base growth: 42% Cumulative procedures: 14,103 procedures +5 more
Global installed base
238 systems
As of September 8, 2026
Installed base growth
42%
Versus 168 systems at the end of 2025
Cumulative procedures
14,103 procedures
As of September 8, 2026
Procedure growth
79%
Versus 7,885 procedures at the end of 2025
Pediatric robotic surgeries
258 surgeries
As of August 31, 2026
Robotic telesurgeries
188 telesurgeries
As of August 31, 2026
FDA review timing
End of Q1 2027
Expected completion of the SSi Mantra 510(k) review
EU CE marking timing
End of 2026
Company expects certification can be obtained by this date

Historical Context

3 past events · Latest: Aug 13
3 events
  1. Aug 13

    Earnings report

    24h Move
    +3.8%

    Reported 224 installed systems, 12,272 surgeries, and continued FDA and CE review timelines.

  2. Jul 17

    Surgical robotics showcase

    24h Move
    +0.8%

    Reported 12,375 procedures, 178 telesurgeries, and 225 pediatric surgeries on SSi Mantra.

  3. Jun 30

    Industry award

    24h Move
    +17.6%

    Reported 11,719 procedures, 175 telesurgeries, and 212 pediatric surgeries.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

510(k) premarket notification, ce marking, telesurgery, pyeloplasty
4 terms
510(k) premarket notification regulatory
"FDA will complete its review of the Company’s 510(k) premarket notification"
A 510(k) premarket notification is a regulatory submission to the U.S. Food and Drug Administration that shows a new medical device is as safe and effective as an existing, legally marketed device. Think of it like demonstrating your new model performs like a trusted older model so it can be sold; for investors, 510(k) clearance is a key hurdle that affects how quickly a device can reach market, development cost, and the level of regulatory risk in a medical-device investment.
ce marking regulatory
"a European Union CE marking certification can be obtained by the end of 2026"
CE marking is a symbol placed on certain products showing they meet European Union safety, health and environmental rules required to sell them in the EU/EEA. For investors, it signals that a product has cleared a common regulatory hurdle—like a passport for market access—reducing legal and market-entry risk and often widening sales opportunities across European markets.
telesurgery medical
"perform a successful robotic telesurgery between Colombia and India"
Telesurgery is performing an operation when the surgeon is in a different location from the patient by using robotic instruments, high‑speed data links and real‑time video so the surgeon controls tools remotely—think of a surgeon using a precise, medical version of a game controller to operate through a machine. It matters to investors because it can expand access to specialized care, create new markets for surgical robots, software and connectivity, and change hospital costs and payer dynamics as adoption, regulation and technical reliability evolve.
pyeloplasty medical
"perform a robotic pyeloplasty on a 45-day-old baby"
Surgical repair of a blockage where the kidney's drainage area meets the tube that carries urine to the bladder (the ureteropelvic junction); surgeons remove the narrowed segment and reconnect healthy tissue so urine can flow normally. Like fixing a clogged section of plumbing between a sink and its drain, the procedure restores function and can be done through open, laparoscopic, or robotic approaches. It matters to investors because procedure volume, device use, reimbursement and clinical outcomes affect hospitals, medical-device makers and healthcare revenues.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

-- Advancing global expansion, pediatric robotic surgery and telesurgery --

-- Growing SSi Mantra installations, procedures and utilization --

FORT LAUDERDALE, Fla., Sept. 10, 2026 (GLOBE NEWSWIRE) -- via IBN -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (NASDAQ: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today provided an update on the Company’s continuing progress and milestones.

Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations, commented, “Our advanced, cost-effective SSi Mantra surgical robotic system (the “SSi Mantra”) is benefitting lives globally, one patient at a time, from a 45-day old baby needing kidney surgery in India to a cardiac patient in Sri Lanka.  Our progress in democratizing access to state-of-the-art surgical robotic care continues to be reflected in growing SSi Mantra installations, procedures and utilization.”

Recent Company Progress and Milestones:

Global Expansion

    • Colombia.  On July 29, 2026, Dr. Sudhir Srivastava officially launched the robotic cardiac surgery program at La Fundación Cardiovascular de Colombia (FCV) in Bucaramanga, Colombia, performing the country’s first Totally Endoscopic Beating-Heart Bypass Surgery using the SSi Mantra surgical robotic system. 
    • Sri Lanka.  On August 23, 2026, Kings Hospital Colombo installed the first SSi Mantra surgical robotic system in Sri Lanka, marking the official launch of the medical center’s robotic surgery program. Following its installation at Kings Hospital, the SSi Mantra has been utilized to perform the country’s first robotic-assisted cardiac surgery and over 25 other robotic surgeries within the first three weeks of operation. 
    • Global Installed Base.  With the installation in Sri Lanka, the SSi Mantra’s global installed base now spans 12 countries, including a leading presence in the Company’s immense home market of India.
    • US and EU Regulatory Review. Looking ahead, SS Innovations expects that the U.S. Food and Drug Administration will complete its review of the Company’s 510(k) premarket notification for the SSi Mantra by the end of the first quarter of 2027 and believes that a European Union CE marking certification can be obtained by the end of 2026.

Pediatric Robotic Surgery 

    • Intricate Robot-Assisted Pediatric Surgery.  On August 14, 2026, the Company’s SSi Mantra surgical robotic system and 5-millimeter instrumentation were utilized by Dr. M. Ramalingam to perform a robotic pyeloplasty on a 45-day-old baby at Hindusthan Hospital in Coimbatore, India. The infant recovered rapidly after successful completion of the complex yet minimally invasive kidney procedure. This accomplishment represents another proof point for the SSi Mantra’s capabilities in pediatric robotic surgery, which involves the smallest patients and requires superior precision and control during suturing and cutting, among other surgical tasks.  
    • Cumulative Pediatric Surgeries. As of August 31, 2026, a total of 258 pediatric robotic surgeries have been completed with the SSi Mantra. 

Robotic Telesurgery 

    • Longest-Distance Telesurgery.  On July 29, 2026, a team of surgeons led by Dr. Sudhir Srivastava utilized the SSi Mantra to perform a successful robotic telesurgery between Colombia and India, spanning more than 13,600 miles (22,000 kilometers) of fiber network distance and eclipsing the previous longest-distance telesurgery record also held by the Company.  The telesurgery, a robotic sleeve gastrectomy, was performed remotely from Hospital Internacional de Colombia in Bucaramanga, Colombia on a patient located at Mohak Bariatrics and Robotics in Indore, India.
    • Expanding Ecosytem in India.  On August 9, 2026, Ahmedabad, India-based Shalby Hospital joined an expanding ecosystem of healthcare institutions utilizing the SSi Mantra to perform robotic-assisted telesurgery. Three surgical procedures were successfully performed remotely from SS Innovations’ headquarters in Gurugram, India, more than 590 miles (950 kilometers) from the patients at Shalby Hospital.
    • Launch of Telesurgery in the Philippines. On September 5, 2026, the SSi Mantra was used to perform the first telesurgery within the Philippines between Pampanga and Cotabato, a distance of approximately 1,070 miles (1,710 kilometers).  
    • Cumulative Telesurgeries.  As of August 31, 2026, a total of 188 robotic telesurgeries have been completed with the SSi Mantra.

Increasing Utilization and Scale

    • 50 Robot-Assisted Surgeries in a Single Day.  On August 15, 2026, the surgical team at Mohak Bariatrics and Robotics in Indore, India utilized five separate SSi Mantra systems to successfully complete 50 robotic general surgery procedures in a single day, demonstrating the robustness of the Company’s technology. 
    • Practice and Hospital Milestones. Numerous practices and hospitals across India and abroad are surpassing the 200+, 100+ and 50+ procedure milestones with the SSi Mantra, indicating growing utilization and ability to scale.

Growing Installations and Procedures

    • More than 14,000 Successful Procedures.  As of September 8, 2026, the SSi Mantra cumulative installed base totaled 238, up 42% from 168 at the end of 2025 and the number of multi-specialty procedures completed with the SSi Mantra totaled 14,103, up 79% from 7,885 at the end of 2025. 
    • Broad Pool of Surgeon Users. To date, approximately 1,500 physicians have been trained on the SSi Mantra, which has been utilized to perform over 170 different types of surgical procedures.

About SS Innovations
SS Innovations International, Inc. (Nasdaq: SSII) develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The Company’s product range includes its proprietary “SSi Mantra” surgical robotic system and its comprehensive suite of “SSi Mudra” surgical instruments, which support a variety of surgical robotic procedures including cardiac surgery.  Headquartered in India, SS Innovations is a U.S. company focused on expanding the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions.  Visit the Company’s website at ssinnovations.com or LinkedIn for more information and updates.

About the SSi Mantra
The SSi Mantra surgical robotic system is a user-friendly, modular, multi-arm system with advanced technology features, including: 3 to 5 modular robotic arms, an open-faced ergonomic surgeon command center, a large 3D 4K monitor, a touch panel monitor for all patient related information display, a virtual real-time image of the robotic patient side arm carts, and the ability for superimposition of 3D models of diagnostic imaging. The optional SSi MantrAsana tele-surgeon console is a portable, compact alternative to the SSi Mantra’s standard surgeon command center that provides equivalent control functionality while enabling enhanced portability, ergonomic flexibility, and telesurgery capability. The SSi Mantra utilizes over 40 different types of robotic endo-surgical instruments to support different specialties, including cardiac surgery, and 5mm instruments for the pediatric population and ENT surgeries. A vision cart provides the table-side team with the same magnified 3D 4K view as the surgeon to provide better safety and efficiency. The SSi Mantra has been clinically validated in India in more than 170 different types of surgical procedures.

Forward Looking Statements
This press release may contain statements that are not historical facts and are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. The words “anticipate,” “assume,” “believe,” “estimate,” “expect,” “will,” “intend,” “may,” “plan,” “project,” “should,” “could,” “seek,” “designed,” “potential,” “forecast,” “target,” “objective,” “goal,” or the negatives of such terms or other similar expressions to identify such forward-looking statements. These statements relate to future events or SS Innovations’ future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.

Investor Contact:
The Equity Group       
Kalle Ahl, CFA             
T: (303) 953-9878       
kalle.ahl@theequitygroup.com

Devin Sullivan, Managing Director
T: (212) 836-9608
devin.sullivan@theequitygroup.com

Media Contact:
RooneyPartners LLC
Kate Barrette
T: (212) 223-0561
kbarrette@rooneypartners.com

Corporate Communications:

IBN
Austin, Texas
IBN.Ai
512.354.7000 Office
Editor@IBN.Ai


FAQ

What recent international clinical milestones did SSi Mantra achieve?

Recent milestones include Colombia’s first totally endoscopic beating-heart bypass surgery at La Fundación Cardiovascular de Colombia on July 29, 2026, and Sri Lanka’s first robotic-assisted cardiac surgery plus over 25 additional robotic surgeries at Kings Hospital Colombo within the first three weeks after installation.

What progress has SS Innovations reported in pediatric robotic surgery?

On August 14, 2026, SSi Mantra with 5-millimeter instruments was used to perform a robotic pyeloplasty on a 45-day-old baby at Hindusthan Hospital in Coimbatore, India, with rapid recovery reported after the minimally invasive kidney procedure. As of August 31, 2026, a total of 258 pediatric robotic surgeries had been completed using SSi Mantra.

How is SSi Mantra being used for robotic telesurgery and over what distances?

On July 29, 2026, a telesurgery sleeve gastrectomy was performed remotely between Colombia and India over more than 13,600 miles (22,000 kilometers) of fiber network, surpassing the company’s prior distance record. Additional telesurgeries were conducted between Gurugram and Ahmedabad, India over about 590 miles (950 kilometers), and within the Philippines between Pampanga and Cotabato over approximately 1,070 miles (1,710 kilometers). As of August 31, 2026, 188 robotic telesurgeries had been completed with SSi Mantra.

What utilization and scalability milestones have hospitals achieved with SSi Mantra?

On August 15, 2026, Mohak Bariatrics and Robotics in Indore, India used five SSi Mantra systems to complete 50 robotic general surgery procedures in a single day. In addition, multiple practices and hospitals in India and abroad have surpassed 200+, 100+ and 50+ procedure milestones with SSi Mantra, indicating growing utilization and scalability.

What regulatory timelines does SS Innovations anticipate for SSi Mantra in the U.S. and EU?

The company expects the U.S. Food and Drug Administration to complete its review of the 510(k) premarket notification for SSi Mantra by the end of the first quarter of 2027 and believes that European Union CE marking certification can be obtained by the end of 2026.

Keep reading